Spots Global Cancer Trial Database for Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
Official Title: Phase III Study of the Comparison of Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer. A One Year Randomised, Open Label, Multi-Centre Phase III Trial.
Study ID: NCT00841113
Conditions
Study Description
Brief Summary: To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.
Detailed Description: Inclusion Criteria * Males over 18 with documented advanced or metastatic prostate cancer Outcome measures * Comparative castration rates one week after starting therapy * Degree of testosterone surge in the first month of treatment. * Maintenance of medical castration during one year of therapy. * Comparison of the treatments on QTc prolongation
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Contact Details
Name: Frans M J Debruyne, MD
Affiliation: University Hospital Nijmegen
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
